Get started
Author

Lewis K. Penny

Observed names: Lewis K Penny, Lewis Kirk Penny, Lewis Penny, Penny, Lewis K.
ORCID: 0000-0002-3722-4476
Observed ORCID: 0000-0002-3722-4476
OpenAlex ID: A5000948331
The challenges for cancer chemoprevention
2015 · Lewis K. Penny, Heather M. Wallace · Chemical Society Reviews · 81
Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
2023 · Alex Zabala-Findlay, Lewis K. Penny, et al. · Cells · 39
PDF
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
2023 · D. Angioni, O. Hansson, et al. · The Journal of Prevention of Alzheimer s Disease · 22
Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force
2023 · Maria Soto, P. Rosenberg, et al. · The Journal of Prevention of Alzheimer s Disease · 20
Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
2020 · Mohammad Arastoo, Richard Lofthouse, et al. · International Journal of Molecular Sciences · 20
PDF
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
2024 · Lewis K. Penny, Richard Lofthouse, et al. · Translational Neurodegeneration · 19
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease
2026 · Claude M Wischik, Richard Stefanacci, et al. · The Journal of Prevention of Alzheimer s Disease · 10
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease
2024 · Mohammad Arastoo, Lewis K. Penny, et al. · Alzheimer s Research & Therapy · 9
PDF
Significant dose‐dependent reduction in neurofilament light chain concentration in plasma with oral tau aggregation inhibitor hydromethylthionine mesylate
2023 · Claude M Wischik, Bjoern Schelter, et al. · Alzheimer s & Dementia · 2
PDF
Mechanism of core-tau unit assembly and inhibition in Alzheimer’s disease
2024 · Michael P. Mazanetz, Karen E. Marshall, et al. · Research Square · 1
PDF
Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model
2026 · Lewis K. Penny, Mohammad Arastoo, et al. · Alzheimer s Research & Therapy
Additional file 1 of Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model
2026 · Penny, Lewis K., Arastoo, Mohammad, et al. · Figshare
Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model
2026 · Penny, Lewis K., Arastoo, Mohammad, et al. · Figshare
Quantification of plasma tau species containing the proline-rich region as a biomarker in Alzheimer’s disease
2025 · Mohammad Arastoo, Lewis K. Penny, et al. · Scientific Reports
PDF
3D measurement of large quantities of cilia in ImageJ/FIJI
2016 · Marek Szulc, Linus Muellerschoen, et al.
Works count: 17
Citation count: 223
H-index: 8
I10-index: 7
Year
Topic
Type